TriSalus Life Sciences, Inc.
TLSI
$4.19
$0.112.70%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 14.17% | 3.15% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 14.17% | 3.15% | |||
| Cost of Revenue | -7.56% | 5.77% | |||
| Gross Profit | 18.46% | 2.65% | |||
| SG&A Expenses | -10.03% | 5.29% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -19.94% | 10.97% | |||
| Operating Income | 63.71% | -22.94% | |||
| Income Before Tax | 9.74% | -30.33% | |||
| Income Tax Expenses | -100.00% | 266.67% | |||
| Earnings from Continuing Operations | 9.79% | -30.44% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 9.79% | -30.44% | |||
| EBIT | 63.71% | -22.94% | |||
| EBITDA | 64.47% | -23.50% | |||
| EPS Basic | 78.28% | -317.51% | |||
| Normalized Basic EPS | 68.22% | -13.62% | |||
| EPS Diluted | 78.28% | -317.51% | |||
| Normalized Diluted EPS | 68.22% | -13.62% | |||
| Average Basic Shares Outstanding | 8.80% | 30.52% | |||
| Average Diluted Shares Outstanding | 8.80% | 30.52% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||